Axsome Therapeutics (AXSM) 6 Nov 232023 Q3 Earnings call transcript

Good morning, and welcome to Axsome Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions].

As a reminder, today's conference is being recorded.I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer, Axsome Therapeutics. Thank you. Please go ahead.

you joining thank conference on and call. morning, all us for today's Good issued release for earnings update morning, our This we press of of company's quarter and the providing financial third results the XXXX. details corporate a release and available ago on short axsome.com. is at the a website The crossed time wire our

intended present plans, utilization making clinical clinical from uncertainties of statements call, including future to the among efficacy, periodic the commercial other cause of development be filings statements. of anticipated and investigational statements additional expectations our certain our intended materially agents, that contained our reports. today's investments. our These conduct and possible nonclinical the During on the and Securities differ information, and and change that in with plans and Auvelity our to or quarterly data, trials, our and use report in will These involve may assumptions Commission, the plans, revenue forward-looking These pipeline current and Exchange forward-looking cash risks and and plans may are Sunosi, source research and risks annual based described things, are safety future regarding forward-looking results projections made we actual those include to our subject plans, regarding, other are statements. costs, and statements regulatory and

these are forward-looking You to are made which such obligation on company of to statements, and update reliance not the today's any disclaims cautioned undue place as only date, statements.

as Vice progress the Officer; of upcoming provide Officer; milestones. call and Dr. the Strategy. Herriot overview well Nick Financial will key Chief XXXX third Chief President company the Tabuteau Product are Executive on me and as of in today of Joining Lori quarter made Englebert, Executive an Pizzie, Herriot

update. a Herriot, will review results, will commercial our then Following provide Nick financial Lori

I order with are will line be received. taken then the will that, for will call Herriot. over the Questions to turn in they We open the And questions.

details contributions Sunosi. year-over-year year. sequential X significant receptor reflects Auvelity, efficacy date a will Auvelity will reflects its both Lori Third the differentiated Thank Financial the progress on well quarter's NMDA commercial commercial thank delivering and antagonist new our Good commercial our additional receptor Update neuroscience demonstrated performance. Its and clinical us and Business showing into go quarter-over-quarter call, now Therapeutics' patients in onset XXXX Quarter late-stage morning, Axsome and quarter In million, positions to the strong joining potentially you, Results broad Mark. Call. our serious we The and on as to everyone, products and health first-in-class Total revenue agonist as fast provide and third in life-changing brain for continue strong the quarter, our from Nick oral with as advanced quarter in medicines Later net $XX.X you for performance to detail financials quarterly market in well more Sigma-X trials. pipeline. the was to care growth. The providers. lasting representing product been has the disorders our on and Conference

enabled While surface we we scratched commercial Sunosi, market believe with that differentiated DCC execution continued date have efficient, are commercial to digital-centric have effective approach. we reception look clinical medicines.Our proud by has potential to strong Sunosi made and to profiles of or for barely tremendous realize and X and the by We commercialization Auvelity for forward the been success the Auvelity date these progress the our innovative and we for these to opportunities. positive of

drive Auvelity sales with business this to force platform deploy We will continue performance. expanded further to our

pipeline will provide progress, intend the including commercialization late-stage in on the potential for leverage of our A regulatory with upcoming pipeline. brief we our X stage In broad products. anticipated to milestones. the DCC platform some clinical I and addition, update fully Starting the a

treatment of are NDA first working on resubmit on which for the In for are track of for submission quarter the parallel, For migraine, track management fibromyalgia, half AXS-XX the we also XXXX. this acute XXXX. for on for is submission candidate product we to of the first AXS-XX the in the NDA in of

track in III potential a top to programs. initiated in ADHD, solriamfetol Moving this on III we develop of we III AXS-XX eating clinical first quarter and for of XXXX. In treatment with trial for for the are to complete The new on options. XXXX. Phase and sleepiness with track first narcolepsy of enrollment XXXX. to II the previously Phase announced treatment we the for of agitation treatment shift of ADVANCE the indications solriamfetol the and completion focused of limited patient of disorder Phase second significant this These AXS-XX that with our of is binge of line Phase populations for The on the III the in half trial X in We of trial results intend of Symphony of expected half treatment completion work disorder. excessive disease year trial anticipate July, announcement is associated treatment Alzheimer's

this the solriamfetol will be of of the performance first development binge disorder progress work are III pipeline. initiate and commercial track provided about saw us We end quarter shift of eating details programs by to before on to Further Phase significant our at Overall, end. these make year in the in held XXXX. a solriamfetol Investor and with clinical third in trials planned year's quarter be Day disorder

out this turn expect will our performance. now to call close provide details of stage will We financial the I the XXXX. Nick, year for setting productive who execution, strong with continued to

the commercialized and million the X quarter and royalty Sunosi the for $XX.X was versus net stock-based products, Selling, period associated sales of period in the of in for for our million due for stock-based in related higher and of of due advancement $XX.X XXXX. The million build-out launch. $XX.X period. AXS-XX Herriot consisted year-over-year expense current equivalents per million that revenue $XX.X million only loss and in ongoing sales commitments the balance Revenue the XXXX.The compared operating in million, the of comprised were no compared third XX% third comparable Research and to year. period for the sales for $X.XX increase million, in were and ended sales for million, period some million you, and the Auvelity in revenue anticipated U.S. NDA focused quarter was based flow sales our Sunosi million, Revenue Thank representing and primarily the both the over or our net the with year $XX.X $XX.X discuss will growth of the We increase net morning. solriamfetol cash XX, to noncash million $X.XX revenue activities Sunosi The XXXX Sunosi $XXX.X timing out-licensed Auvelity Today, reflects including representing general was a and from XX% the $XX.X for $XX.X primarily cash growth for in now million of commercial since growth. to costs product share to XXXX. higher on good territories. was cash commercial $XXX.X of of was consisted to $X.X revenue guidance. costs, sales from quarter until current were the of personnel operations quarter $XX.X of administrative in net plan.I'll and financial quarter was October expenses the in per the quarter in current third higher fund revenue turn with the positivity Sunosi for launched million to Total will was and in comparable revenue believe compensation quarter of Sunosi year-over-year revenue related not net I and $X.X royalty XXXX quarter compensation. Sunosi provide with and to net versus out-licensed Auvelity Sunosi the third of comparable AXS-XX, of comparable to increase for marketing for Auvelity comparable update. ADHD, AXS-XX, XXX%. of net for call AXS-XX comparable trials territories. or sequential sales XXXX. trial million. who versus results the December Auvelity XXXX. period million representing third provide sufficient was MC volumes $XX.X period the Lori, the was Cost share teams. loss million and $XX.X a both commercial expenses post into and the in cash Auvelity Net in million noncash quarter $X.X the is development We the prior as Sunosi the net $XX.X of

you, good both morning, despite typical and Sunosi Thank market and Nick, strong Auvelity quarter, In third everyone. delivered growth the seasonality. results

Auvelity, starting week profile fast clinical new milestone profile. X growth. all full to favorable that improvement of For Auvelity being XX up this are recently reflecting with rapid with year. the lasts the on months, market sustained and a demand durable at reached in has We depression an for accelerating focused of tolerability on Market very X we remain symptoms and been reception positive, treatment. works effects important treatment

prescriptions added representing of market growth. market and brands resulting the decline and quarter is same quarter, period In to Auvelity. impacting in are our X Both lives for due the year-over-year the launch seasonality. post approximately full patients, growth third beyond. performance for Auvelity, For relaunch the we the expect This for are represents XX% to only written as continued overall quarter-over-quarter In efforts from the QX prescribers Sunosi, approximately in antidepressant solid a quarter total contrast number subscribing during new in X% Auvelity, growth and of to XX,XXX unique In meaningfully were new at cumulative quarter-over-quarter. launch of bringing XX,XXX third we as growth depth since increased the total of well prescribers. to the ACP to XX,XXX. breadth than start of third quarter, QX. increasing Prescription Auvelity both for quarter, first-line increased with X,XXX prescriptions patients, launch an prescribers the end an the adopters more of of XX,XXX of came since approximately HCPs patients new wrote

force by earnings during $XXX. we As to in the loss about our representatives total XXX Auvelity to expanding QX call, sales response growing approximately success of and sales demand, early a are our mentioned

by will prescriptions commercial approximately track discussions QX the of regards substantially with which reach on deployment expansion established for Auvelity, channel, full are write evolve. increase In and will of to more the volume patients. prescribers. of With currently of In now approximately of XX,XXX of payer greatest These covered from complete prescribers are coverage have is all first XX,XXX The quarter. to the for lives help with end to new-to-brand of Medicare and channels, lives. covered. in to coverage reach training Medicaid hiring and we coverage expanded Active potential HCPs expands XX% as at coverage, the approximately the We and represents XX,XXX team our our completed continue the the XXX% payers XX% XX% covered increase lives. and source

increased summer to our unique in Sunosi's prescribers. XX% patients total added Sunosi last last new for increase of the U.S. new Auvelity, Like Sunosi and to have breadth Since can demand the Since of investments for Turning attributed to patients, which year, clinical an broad, Sunosi growth within covered. the prescriber differentiated sequentially. to has unique steady XX% in year-over-year Total grew the of team decline work riders promotional by past Sunosi. commercial XX% by profile. XX,XXX and expected driving Payer unique remains base year. The continues seasonality. in lives be current Sunosi over and due The year, quarter QX XX% QX of with overall growth experienced XX%. lives despite field prescriptions debt new market the meaningful both represents Sunosi cumulative we adding third coverage of of Sunosi and of X% on focused

in product to our continued the promotional efforts expect growth current indication. We the drive for

has turn focused the Sunosi on lead binge including call disorder. new will We ADHD, unmet growth potential the remain In disorder these strong commercial to differentiated both Auvelity and in eating Mark indications, high Sunosi performance now treatments, to to address patient discussion. with of delivered works significant the Overall, and clinically potential addition, execution target populations needs.I in Q&A shift maximize the back which quarter.

have Thank Lori. our you, please we Operator, first question. may

[Operator Instructions].

Cantor Our from Duncan question is first today coming Charles Fitzgerald. of

to pipeline. One one Herriot it. Perhaps answer for is whoever and had a really quarter. commercial, Lori team, or congratulations nice wants I a on couple. is

Or Regarding drivers still wondering -- revenue. of Are are of it more versus in on persistence? that Auvelity, demand I'm the wondering patient about of the the longer adds in Because seeing you you new starting I'm would you in antidepressant. me result drivers for to patients terms being about expect to product would see persistence? seem might drug profile than the well,

Charles, we're that I'll It still take that working one question. is through.

just hit X-year have our We mark.

hear the prescriptions the tick per about rapid But we're Auvelity. in it's about you the of than a on on, mark, onset all working refill what comment of to as the we the particularly just past bit Feedback, the anything is from for heard persistence are was seeing well still We're rates anecdotal product So different what effect. that hard Early durability as feedback, X-year label. the to would starting anecdotal though, action. we from now an long-term we're seeing feedback not therapeutic really area. expect

fast HCPs see So healthy we're anecdotal the with the is just seeing a refill treatment. and through is that both going we're prescriptions, new to consistent answer of new And still evidence and and on pleased I a the basis. are from which just and patients. driving the that number patients laps, that are We're starting patient response weekly patients. clinicians it very of number that's feedback product continuing was to acquisition getting of

you are you're you're a For next like is through Nick, yet yet? not that contemplating now giving there? Or guidance year? that not year, you Do feel

difficult and point. on. ponder as to that We'll we're so year are closer XXXX, end towards many think this early guidance continue point that still the we is get the a but at I at into bit variables there of this Yes, giving

by, hear I the stand I'll So question, Charles. but

bullish first disease the characterize half. intrigued the that Alzheimer's about had a you're wondering on, are in Maybe different. that regarding enrolling And Alzheimer's being with far. you that I'm Or really ADVANCE a out thus obviously, is wondering, 'XX. read across diagnosis? blinded I'm disease, all How could if area a on pretty able X you patient agitation. presentation the the to about I'm pipeline, question neurodegenerative disease confirming sample basis symptom not you I sound in

And so to confirm of need you don't diagnosis Alzheimer's. really

as The matching way ones also the that disease A studies well-accepted validated match that same scales confirm well we ADVANCE-X we're the we trial. in trial is patient And diagnosis used both the patient the enrolled for in enrolling Alzheimer's sample is or scales in agitation. through the should that sample that are we Alzheimer's ADVANCE-X other as that and and disease. used in for

not doing necessary. correct? you're You feel imaging, that's don't But

doing not are We imaging.

biomarkers? blood-based Nor

We disease pretty enrollment trial, that or for are at that's not for look and biomarkers Alzheimer's standard symptoms. or imaging behavioral the into studies of cognition doing

Leerink coming is question Marc Partners. Goodman next of The from

This for line is Rudy on the Marc.

to expectations the be for this about a adequate support ones that Can your will data a do follow-up for filing talk you Just readout? indication? quick on to X coming And what you think questions. SNDA

disease with And data trial. to in ADVANCE of assume do that I do II has So the agitation. we readouts, Alzheimer’s from question terms upcoming have that,

XXXX. We half expect the complete along the ongoing that filing. our as as the for that, open-label and in basis to studies will first safety the And results trial out form read SNDA from well with prior of the

that to indication? from do data still But need you for in order one file efficacy additional

the trials, ADVANCE-X studies, the X X as The be package in trial, as which study trial. ongoing will well the which are efficacy ACCORD ADVANCE or the

next coming Vikram from Purohit Stanley. The is Morgan of question

this XQ bit there year. narcolepsy, side. it Two from year a slip-on expected of like for from little next of to data a on late One timing our was readout seems

what on is launch, for driven Auvelity Just wanted get what secondly, latest of have might then the And that? of the context breakup lines therapy? on across your sense patients to seeing some you're

line to have take AXS-XX complete have in purely question. year. track expect Lori in I'll the on we driven the to top enrollment. is results With regards we're by we'll enrollment the And the to first and of end terms question, the when narcolepsy second of the by study take change

XX% we're seeing XX% XX% we're therapies. the first-line overwhelming have about terms about of therapy, that and prior the the majority to of that now, right the seeing but is majority failed X or patients of type In X are patients

therapy. up or failed So have all or some of XX% brand X X new to

And we're that on I just pleased in launch, or really that are add the either would patients brand of early this new failed treatment. on XX% have

of is from next The Piper Amsellem question David coming Sandler.

Just a couple.

are is esreboxetine about large of GP-focused opportunity, My on and the organization? indication. fit you filing how that thinking a understanding within the commercially it's first, the So

the terms Then is gating just for a this one. that So there drug? reboxetine, your be taking narcolepsy you're you'll for That's in in filing are where it Or to set? where data of does any items expectation filing exactly that number setting other two, the organization? number on fit that

I'll take the first fibromyalgia. one on

an Fibromyalgia You're in generic Only have hasn't Patients, treat very X dollars There now. products time. the all in products been X patient HCPs all to is are the very, U.S. right any widespread. a effective because million right. They're underserved exactly frustrated treat. patients they type approved for very incredibly market, long don't to this with area promotional

right and taking we're have the we'll we state. how highest where on sales make force. state educated us disease field of marketplace, will make speculate really structure strong then making the the we're sure are terms force to HCPs that for to educational the likelihood that in understand our efforts too now on patients to we disease sure And HCPs. that well prescribe sure our focus it's what But on we is premature focusing market, on really way So

add I just said. that Lori And to what

built one enable to us our commercial is approach platform. to that commercial infrastructure of mindful make and we designing the always things in I been we've leverage sure to pipeline. that think the the is of

So as Auvelity We're DCC commercialization well happy we're centric is our to platform with Sunosi. really performing the regards digital ready. way or as with

allowing reboxetine that with hone Phase and Phase III ongoing the as even SYMPHONY well better, and fibromyalgia the respect experience to as on will be data data II we question to which make set With consist the launch. is so CONCERT trial, the us that of the trial. it the set will leveraging And it to for filing, your is

is for open-label addition, there is required the trial ongoing an that filing. In extension also

form will those filing. the so X NDA the basis for studies And

The next Jason America. Bank of question is coming from of Gerberry

front, year post we're Firstly, only with just on Paragraph launch surprising, about little a patent single a IV... the a

of have any might what the thoughts then going how your curious, of my So most breadth But rates second there's a And the IP? sleep It views interplay as question to to IP insomnia III competitively end, on generics maybe drug that's and very but an with on orexins limited is are your get may be going Perhaps maybe this be they since first going challenges the with flip side, be disorder here? just real might the maybe trade-off file. trend your a could given can't on Paragraph on have potent looks like trade-off. 'XX. narcolepsy specifically MWT to

just of orexin emerging profile on with your that So interplay how could competitively thoughts XX’. the curious and

Hunter this Jason, is Murdock.

can you ongoing practice, any we're legal comment we and very comments matter really don't we further a on portfolio have As on it. Auvelity, our on of extensive tell But proud of proceedings. can't I

around know, our like touch impact And approved with primary sleepiness we Phase And orexin for and on III question have treat have patients I'll Sunosi, study they cataplexy. then AXS-XX. trial. the active that portfolio, We that do waiting the how with of narcolepsy. as readout the And we is the endpoint which maybe is you we're market. and in And to daytime your might

I'll to market disease symptoms think So of and the let patients these aspects Lorie be is that of the and cognizant about talk when of one we multiple need, experience. about that, are the there that the

each treatment So will no one address system.

address should one of than our portfolio, able which like be those Lori? more we sentence, to So

approved for market And They versa. and to now, have off trade on vice difficult efficacy tolerability schedules. the of those or really that endure dosing are right patients

need unmet So in orphan this there is indication for still patients. a high

question coming of is June from next Securities. Truist The Lee

the storable for niche I a commercial eating have a are either it opportunity prevalence like for binge soriacitol? framing the of Binge opportunity. could and How follow-up. a eating And sounds be in U.S. you or huge

disorder. very is estimated potential about the very, now, We most prevalence only available are treatment excited very for is It $X also limited the options eating patients. the disorder. eating here common are binge right million for

a in need incredibly disease unmet high prevalent. again, is that So

On your statistical would the EDS? not sleepiness hitting is good Or a narcolepsy goal on to and on is outcome? significance hit cataplexy, both on significance but excessive statistical it study, daytime cataplexy

speculate cataplexy, The we're we're primary would in intent going not of and close. of or what the could terms results to the study is be be,

So very you'll know soon.

Ram coming is Selvaraju The of next H.C. from Wainwright. question

your for disorder. First one is as and if competitive what you indication? on secure binge be for you expect candidate might this Can the clarify to maybe eating drug any, label us it for a landscape, when

SSRIs, I It there binge now, highly think, disorder. disorder, prescribed is is SNRIs again, one available eating prevalent the Right is, for product for being generic.

we think the ourselves to opportunity an in we differentiate So really marketplace. clinically have

refresh ultimately, promotion strategically, that And with activities, how ultimately, for you already And then line in for regarding if in out label the sales you field? and with regard can a smoking just indication memory you that indication, expect dovetail assuming your have to what sketch cessation. could activities to us time marketing you my just

our contestation an psychiatry obvious and is overlap for terms of in neurology There of the therapeutic and rest small pipeline. area

like it clinical think will we depend our evolves the concentration. a So from as III And Phase I upon the lot profile trials.

Joseph question coming of is from Cowen. TD Thome next The

the then that? the popped CTAD, call to Are on that you seeing Or period. like impact core by first given Or QX higher that up a on the earlier? of thinking like TEAE, as going at one bit data but they looked is physicians? more are the first go And incremental points? group about on presented Maybe additional primary it the specialists care Can that? additional the these more And are sales the XXX% dizziness into quarter, the you little be force. went should the from weren't largest X end you second, a in impressively double-blind to expect then that how detail we

go grade can of just about AE. Does bit So dizziness a what away AXS-XX? time? little that with you with And the talk is this

expansion. the address I'll

quarter As number. to memory everyone's HCP remained last PCPs what are basis. focused readout, about is on weekly of higher That refreshed take force the XX,XXX new a HCPs, targets. we our at into that this and mentioned sales we XX,XXX XX,XXX HCP we those targets likelihood expanding will from highest branded therapies have But they on to XX% prescribe Of of HCPs. writing are a number

the like So the opportunity feel to product. optimize have of great we we growth a

regards And around the with the dizziness to [indiscernible] trial. question

Your over transient. was did time correct. dizziness decreased result a in It It discontinuations. it observations The was mild. and not are

The from Suneja Guggenheim. is of next question coming Yatin

is Eddie This on [indiscernible].

force quarter-over-quarter Just before for really until script we light do wait do one And force about inflection increased Auvelity? the to to from sales us. of show later quarter, in you increased how increases then? there? think think XXXX expect should see sales Or you we In we have this increasing an the the cadence

there and before, QX, by but field trade in hired take As a and new produce. time little establish for should the have does themselves reps get out sales we to promoting mentioned to it we

So any year. we in the until meaningful later expect don't uptick

question next of is Securities. The Graig coming from Suvannavejh Mizuho

in sales then both any and third just could Sunosi changes products reflected for on comment if was I I in And you both for net and Auvelity have wondering quarter a to whether please follow-up, good third on the a please. inventory? quarter. quarter gross reported Congratulations

had from an XX in was in approximately for quarter. That The GTN saw was where quarter that as to gross low that we net was discount the well Sunosi to similar in the the to which previous the very previous in mid-XXs. quarter, XX%. improvement Auvelity a was low

As we've roughly we channel. X it of to always maintain weeks relates inventory, that, inventory in shared

So neither there Sunosi. for the as relates for Auvelity it inflection or no sales inventory to was

there. trajectory see I then And

you sales like on given OSA look you but should I'm if might what You've million that done sales there and between a dynamic how peak to out nice peak time mix? the put comment we just maybe $XXX $XXX product, expect to wondering of narcolepsy and the million, can

and onto anything answer want there's else add. Nick I'll then you to if

and about right between XX,XXX narcolepsy about now, be expected. to XX So XX,XXX. split narcolepsy. OSA is narcolepsy is That's million to OSA, the patients, OSA is XX% XX% prevalence whereas

continue So patients, do to Right treated. drug only now patients OSA of those expect, million say, X let's we increase. to about actually XX million are

So OSA our several disease, will very are understanding efforts peak with of the and started ago. and to have increased doing come which heavily sales quarters treating path and we doing in education

So we peak that, anticipating will will are that follow. effort sales be promotional continue and

And announced thing expect continuing market, add our I'll is U.S. the perspective, other up significant grow we to that and seeing earlier. And really there's pharmanovia And the ramping sales nicely their maybe as it revenue relates the strategy. very while we're been ex was in start with U.S., royalty strategy. marketing would international and Pharmanovia that sales to a refocus the from Pharmanovia is to transaction

Blair. The Myles coming from William Minter next question of is

there quarter. care primary quick guys Myles. physicians referral have read-through options? any mix between specialty approved do ones then learnings any you see And X approval AXS-XX about You've on disease great goals another internal accounts? And got recently Do the how us. secondly, the from Congrats is in that Alzheimer's from differentiating Sarah or prescribing on and from you for agitation? Auvelity Rexulti

first take I'll the one.

that goals, typically it of look way. at we terms don't In

most that at likely novelty prescribe. that a that's now, Right sets, market. to take bit. there's come are a broader to out psych, product with XX% we a little PCP with the mentioned, Consistent expansion prescribers As about our new to our and PCP, action and we XX% look mechanism be to level of especially do to expand out as we expected, expect

differentiated development there, we been consistent. learnings like clinical trials, Rexulti. will been to is which our our with Rexulti Alzheimer's thus and from plan think And relates agitation. it remain completed that profile happy And disease regards as far with it regards from to AXS-XX any and have we've to with We the clinical and

from The is of last coming Kaplan question Thalmann. Ladenburg Matt

strong Congrats quarter. on the

to about you little terms the And there? need wanted what opportunity for talk ADHD Sunosi can there? unmet Lori maybe bit Just more, the is of in market the to describe and a potential the

at we're market market it have as and about and The safety a risks very across way sizes adolescents now, we the as XX evaluating Stimulants take condition. do but about really and safer, very non-stimulants up a are effect can for effect they solriamfetol. along monthly basis. your for non-stimulants. the ADHD break It's ADHD think prevalent prescriptions really Again, sizes. is lots while are way on is a look adults million, about that that come rather but into so excited of have and that large highly well pediatrics Prevalence market you the they stimulants with, less have now large right

So and we solriamfetol opportunity for ADHD. are excited again for the

for At this concluding I'd like back any the to turn to remarks. time, CEO, over Axsome's call

the and Well, thank of you the we industry-leading us, today's by progress by call. Auvelity all excited our of ahead team efforts Axsome. for at We're our as joining both opportunity us to made CNS pipeline. outstanding Sunosi am on I proud continue

regulatory milestones on and the XX we on XXXX, value-driving out months. on As next we track fronts clinical close to over multiple are deliver potentially the

our on progress. a day. products Our marketed to deliver rest look team you updating great X XXXX. potentially at of to hard forward Have is having on our working of goal your We least by

participation. your thank concludes gentlemen, event. you This for today's and Ladies

time after of enjoy rest disconnect at come day. may your this back the and You lines, your webcast